7月8日 - ** 药物开发商 Cargo Therapeutics CRGX.O 股价盘前上涨 9.6%，报 4.81 美元
** Concentra Biosciences将以约2.0197亿美元的全现金交易收购CRGX
** 要约对 CRGX 的估值为每股 4.38 美元，外加不可转让的或有价值权$(CVR)$
** CVR将获得交易后两年内CRGX某些药品净收益的80%，以及Co超过2.175亿美元的期末净现金的100%。
** 预计合并交易将于 2025 年 8 月完成 - CRGX
** 截至上次收盘，股价年累计下跌 69.56
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.